JanOne acquired the worldwide right to TV1001SR, a twice-daily orally dosed slow-release formulation of the FDA-approved therapeutic sodium nitrite. Results from Phase 2a clinical trials support the use of sodium nitrite for the treatment and prevention of peripheral artery disease (PAD), and as a non-addictive treatment for diabetic neuropathy.
After successful Phase 2a trials, JanOne is advancing TV1001SR into Phase 2b trials planned for the second half of 2020.
Peripheral artery disease (PAD), a chronic disorder associated with reduced blood flow to the extremities. PAD often causes severe pain in the extremities, limits mobility, and in some cases may lead to death. In the US alone, PAD affects nearly 9 million people, and if left untreated will lead to critical limb ischemia with an annual cost of care estimated at $10 billion. The primary cause of the disease is the buildup of fatty acids in the blood vessels, eventually blocking or weakening the vessel walls, ultimately resulting in reduced blood flow to the extremities. Blood clots, diabetes, inflammation, infection and injury can also lead to PAD.
JanOne sees every day as an opportunity for fresh ideas to end the opioid epidemic, the worst drug crisis in our nation’s history.
As a NASDAQ-listed company, JanOne draws private-sector resources into this urgent fight. We seek innovative treatments—focusing on developing revolutionary, non-addictive drugs that kill pain, not people.
February 6, 2020
January 28, 2020
January 23, 2020
March is National Autoimmune Disease month and as we are fighting an “invisible epidemic”, it is a great time to bring awareness. Approximately 23.5 million Americans are affected across the country, according to the NIH.
Best wishes of good health and safety in the days and weeks ahead to all of followers, friends and family.